Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

PR Newswire June 23, 2023

MRSN FRAUD ALERT: Jakubowitz Law is Investigating Mersana Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws

PR Newswire June 23, 2023

MSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws

PR Newswire June 22, 2023

MRSN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

PR Newswire June 21, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

Newsfile June 19, 2023

MRSN INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Mersana Therapeutics (MRSN) Investors With Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

Newsfile June 19, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Mersana Therapeutics (MRSN) Investors With Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violations

Newsfile June 17, 2023

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

GlobeNewswire June 15, 2023

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2023

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 24, 2023

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 4, 2023

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

GlobeNewswire May 3, 2023

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

GlobeNewswire May 2, 2023

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

GlobeNewswire April 26, 2023

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 6, 2023

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

GlobeNewswire March 13, 2023

Mersana Therapeutics Provides Statement About SVB

GlobeNewswire March 10, 2023

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 3, 2023

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 28, 2023